



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 820292.



Health by Advanced Therapies

## Gene Therapy 2.0 - Webinar

### 29<sup>th</sup> September 2021

### RESTORE looks forward to welcoming you to our next online event

The event will be chaired by Prof. Hildegard Büning (Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany)

#### Overview:

Although COVID-19 continues to dominate news channels and social media as well as the interest of public, medical and research communities, research has not stopped on breakthrough technologies and transformative medicine in other indications. Indeed, research continues at full force in academic as well as industry settings on non-COVID-19 topics to ensure continued advancement and development across the board. One of the fields in which intense research and economic activity is evident, is the field of gene therapy. More and more gene therapies are entering the market or are in late clinical development stages, for example Zynteglo (beta thalassemia), Luxturna (inherited retinal disease, Leber congenital amaurosis) and Strimvelis (severe combined immunodeficiency due to adenosine deaminase deficiency). This so-called "classical gene therapy" has established itself as a recognized alternative to older treatment modalities.

However, scientists at the forefront of gene therapy research do not only think about the present, but also about the future, planning for the years ahead and already working to shape the next generation of gene therapies, expanding the realm of what will be scientifically and medically possible.

**RESTORE** will be hosting a half-day online seminar entitled **Gene Therapy 2.0** on **29<sup>th</sup> September 2021** with the intention of engaging and informing academic and industry institutions as well as patient networks, about the most recent updates and opportunities in gene therapy approaches. We hope the seminar, chaired by Prof. Hildegard Büning, will prove informative to those already in the field, foment new connections and inspire others to consider the possibilities for their own research.

**Join us online on 29<sup>th</sup> September 2021 to take a peek into the future!**



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 820292.



# Gene Therapy 2.0 - Webinar

29<sup>th</sup> September 2021

## Agenda

- 14.00-14.05 Welcome**  
Hans-Dieter Volk - Charité Universitätsmedizin Berlin, Germany  
Hildegard Büning - Hannover Medical School, Germany
- 14.05-14.35 Development of AAV vectors from a non-pathogenic virus: a 40 years journey**  
Jude Samulski - Gene Therapy Center, UNC School of Medicine, United States
- 14.35-15.05 Tailoring AAV vectors for in vivo gene therapy**  
Hildegard Büning - Hannover Medical School, Germany
- 15.05-15.35 Lentiviral and alpharetroviral vectors for gene therapy of stem cells and immunotherapies**  
Axel Schambach - Hannover Medical School, Germany
- 15.35-16.05 Genetic engineering of hematopoiesis: choosing the right engineering tool and expanding target diseases**  
Luigi Naldini - San Raffaele Telethon Institute for Gene Therapy and San Raffaele University Medical School, Milan, Italy
- 16.05-16.35 TBA**  
Nathalie Cartier - Sorbonne University, University Hospital Pitié-Salpêtrière, France
- 16.35-17.05 Dressing up viruses to fool cancer: a rapid and affordable immunotherapy**  
Vincenzo Cerullo - University of Helsinki, Finland
- 17.05-17.35 Immunogenicity of gene therapies - measurement and mitigation strategies**  
Hans-Dieter Volk - Charité Universitätsmedizin Berlin, Germany
- 17.35 Closing remarks**  
Hildegard Büning - Hannover Medical School, Germany